News

Is the use of piperacillin/tazobactam for bacteremia caused by ceftriaxone-nonsusceptible Escherichia coli and Klebsiella pneumoniae an obsolete practice?

As clinicians and health care executives work to strike a balance between reducing costs and improving clinical outcomes, the importance of sepsis identification and treatment cannot be underscored enough, and starts with evaluating current practices for infection management.

The US Centers for Disease Control and Prevention (CDC) has announced the investigation of a Salmonella outbreak with a suspected link to Duncan Hines cake mix.

Brad Spellberg, MD, highlights research that indicate shorter courses of therapy are safer and as effective as longer ones, as well as the importance of randomized controlled trials.

Some people living with HIV who have undergone stem-cell transplants have seen a radical reduction in their HIV reservoir. A new study examines the factors that may be behind this phenomenon.

Vascular graft infections are serious complications of reconstructive vascular surgery that may increase patients’ morbidity and mortality.

The current Ebola outbreak in the Democratic Republic of Congo has surpassed 300 cases and international health officials are now questioning if it is capable of being controlled.

C diff and pneumonia still pose significant threats, according to the hospital survey.

A new study on a novel experimental nanotechnology-based organ transplant acceptance therapy offers hope for reduced organ rejection without immune suppression.

The results of a new study suggest these immune-system organs may be more involved in the disease than originally thought.

A new study examining cytokines in the blood of pregnant women infected with Zika may help investigators create a screening test for early detection of fetal abnormalities from the virus.

Highest amounts of Toxocara egg contamination were in areas that could contain food droppings or animal waste.

Data from a pooled analysis of the REVIVE-1 and 2 studies found iclaprim to be non-inferior to vancomycin based on earl clinical response in patients with wound infections.

A new study sheds light onto showerheads as a source for mycobacterial infections.

The results of a phase 1b study may set the stage for the next evolution of HIV therapy.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week

Investigators have found that children who received a flu shot in consecutive years did not see a decline in vaccine effectiveness.

ViiV Healthcare has announced that a long-acting injectable 2-drug regimen has met its primary endpoint in the FLAIR study of virally suppressed adults with HIV.

Investigators have found the quadrivalent vaccination to be as effective as trivalent standard-dose, while the high-dose trivalent was found to be more effective than the trivalent standard-dose.

A long-acting injectable regimen of cabotegravir and rilpivirine has demonstrated high rates of virologic response, long-term durability, and good overall tolerability at 160 weeks.

Keeping communities safe from potentially deadly viruses is everyone’s responsibility.

Drug-resistant mutations in certain HIV strains do not appear to affect disease progression before antiretroviral therapy is initiated, but other variables may play a role.

The results of a new study demonstrate that PrEP can reduce new infections within a population even when the risk of HIV remains high and other proven treatment and prevention strategies are optimized.

Polio could soon be completely eradicated, but public health officials have an intricate set of steps to ensure a lasting defeat.

New outbreaks of rubella and troubling data on influenza highlight the importance of vaccination.

Sanofi Pasteur’s dengue vaccine (Dengvaxia) is moving one step closer to being approved in the United States as the FDA just accepted a Biologics License Application for the vaccine.

Results for SYMTUZA continue to be positive as the latest data indicate that 85% of study participants achieved virologic suppression (viral load